AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Sarepta Therapeutics,, Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S6KJC6
17.73▼ 0.45 (-2.48%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
18.18
Day's Range
17.16 – 18.12
52-Week Range
14.68 – 24.68
Volume
1.3M
Avg Volume
2.9M
Share Statistics
Shares Outstanding
Employees
835
Exchange
XNAS
Listed
1997-06-04
Share count as of July 31, 2026

Sarepta Therapeutics,, Inc. Common Stock (SRPT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Sarepta Therapeutics,, Inc. Common Stock (SRPT)
What is Sarepta Therapeutics,, Inc. Common Stock's Market Cap?
Sarepta Therapeutics,, Inc. Common Stock's Market Cap is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's Enterprise Value?
Sarepta Therapeutics,, Inc. Common Stock's Enterprise Value is $1.9B, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's Price / Sales?
Sarepta Therapeutics,, Inc. Common Stock's Price / Sales is 1.3×, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's EV / Revenue?
Sarepta Therapeutics,, Inc. Common Stock's EV / Revenue is 1.4×, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's EV / EBITDA?
Sarepta Therapeutics,, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's Revenue (TTM)?
Sarepta Therapeutics,, Inc. Common Stock's Revenue (TTM) is $1.4B, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's Net Income (TTM)?
Sarepta Therapeutics,, Inc. Common Stock's Net Income (TTM) is -$136.7M, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's EBITDA?
Sarepta Therapeutics,, Inc. Common Stock's EBITDA is -$98.5M, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's Diluted EPS (TTM)?
Sarepta Therapeutics,, Inc. Common Stock's Diluted EPS (TTM) is -1.29, based on as-reported figures from SEC (XBRL) filings.
What is Sarepta Therapeutics,, Inc. Common Stock's EBITDA Margin?
Sarepta Therapeutics,, Inc. Common Stock's EBITDA Margin is -7.0%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · SRPTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Products, net
Collaboration and other
Total revenues
YoY growth-34.3%-1.9%-32.7%-14.5%
Cost and expenses:
Cost of sales (excluding amortization of in-licensed rights)
Research and development
Selling, general and administrative
Litigation contingency charge———
Amortization of in-licensed rights
Total cost and expenses
% of revenue96.7%51.0%192.9%125.9%
Operating income (loss)
% of revenue3.3%49.0%-92.9%-25.9%
Other (loss) income, net:
Other (expense) income, net
(Loss) income before income tax expense (benefit)
Income tax expense (benefit)
Net (loss) income
% of revenue-1.2%45.3%-63.9%-45.1%
Other comprehensive (loss) income:
Unrealized (losses) gains on investments, net of tax
Total other comprehensive (loss) income
Comprehensive (loss) income
(Loss) earnings per share:
Basic
Diluted—